Puma Biotechnology (PBYI) Liabilities and Shareholders Equity (2010 - 2026)

Puma Biotechnology (PBYI) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $192.7 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 1.77% year-over-year to $192.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $806.8 million (down 3.41% YoY) and the FY2025 annual result came in at $216.3 million, up 1.39% from the prior year.
• Liabilities and Shareholders Equity declined to $192.7 million in Q1 2026, from $216.3 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $230.5 million in Q4 2023 to a low of $192.7 million in Q1 2026.
• A 5-year average of $206.0 million and a median of $202.9 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity fell 25.52% — and 2024, when it gained 9.12%.
• Tracing PBYI's Liabilities and Shareholders Equity over 5 years: stood at $222.1 million in 2022, then advanced by 3.81% to $230.5 million in 2023, then slipped by 7.46% to $213.3 million in 2024, then gained by 1.39% to $216.3 million in 2025, then decreased by 10.91% to $192.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $192.7 million (Q1 2026), $216.3 million (Q4 2025), and $202.9 million (Q3 2025), per Business Quant data.